UMC becomes first hospital in El Paso to earn accreditation for epilepsy care
As a level-three epilepsy center, UMC says it's able to provide 'comprehensive diagnosis and treatment, specialized monitoring, medication management, and surgical capabilities from a multifaceted team of neurologists, neurosurgeons, EEG technologists, neuropsychologists, radiologists and a Neuro ICU team.'
'The work UMC's Neuro team does is unmatched. I commend their dedication to achieving this outstanding accomplishment, which is a huge win for our community. When patients come to UMC, we are proud to provide them with top-tier care supported by the latest medical technology and expertise,' said Jacob Cintron, President & CEO of the El Paso County Hospital District.
UMC says its Neuroscience Intensive Care Unit is comprised of 19 beds and features specialized experts providing around-the-clock care for critically ill patients.
UMC says level-three epilepsy centers have the 'professional expertise and facilities to provide the highest level of medical evaluation and treatment for patients with complex epilepsy, according to NAEC.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 days ago
- Yahoo
DNAKE Emerges as a Global Innovator in Brain-Computer Interface Technology
XIAMEN, China, July 18, 2025 /PRNewswire/ -- Brain-Computer Interface (BCI) technology is redefining human-machine interaction by establishing direct communication between the brain and external devices. This transformative innovation is driving profound societal impact across industries: revolutionizing neurological disease treatment (e.g., epilepsy, Parkinson's, and depression), enhancing educational outcomes through improved focus, and enabling seamless industrial human-robot collaboration. With aging populations and rising neurological disorders worldwide, BCI's healthcare applications are experiencing explosive demand. According to IMARC Group, the global BCI market reached $1.74 billion in 2022 and is projected to hit $3.3 billion by 2027. In this rapidly evolving field, DNAKE is establishing itself as a rising force through cutting-edge R&D and global vision. Technology Leadership & Standardization As a key driver of BCI advancement, DNAKE has forged strategic partnerships with elite research institutions like the CAS Key Laboratory of Brain Function and Diseases, Xiamen University's Brain Cognition & Intelligent Computing Lab, etc. These collaborations underscore its dual strengths: proprietary innovation and integration of top-tier academic resources. DNAKE holds pivotal roles in the BCI Industry Alliance and China Communications Standards Association, actively co-authoring technical standards such as "EEG-Based Attention Monitoring Systems: Technical Requirements and Testing Methods." This standardization expertise positions DNAKE to extend its influence into global markets, where consistent technical benchmarks are critical for adoption. Breakthrough Innovations DNAKE's BCI team recently published groundbreaking research in the Annals of the New York Academy of Sciences, solving a critical industry challenge: environmental adaptability. Their innovative "Human-AI Multi-agent Copilot" system merges EEG signal decoding with deep reinforcement learning AI, enabling devices to interpret user commands while autonomously responding to environmental changes—a leap from one-directional BCI systems to true interactive intelligence. In sleep health, Dr. Phang's team also developed a Multiscale Temporal Convolutional Neural Network (MTCNN) algorithm in the Journal of Neural Engineering that achieves 88.24% accuracy in sleep-stage classification—a 23% improvement over consumer-grade headbands (Miller et al., 2022). This approach sets new paradigms for EEG signal analysis. R&D Commitment DNAKE's 300+ member R&D team includes specialized BCI engineers, with 2024 R&D investment spiking to 11% of revenue. A dedicated $18 million BCI Technology Center will accelerate project commercialization. Strategic Vision Aligned with its "Innovation-Driven Transformation" strategy, DNAKE is pivoting toward digital health ecosystems while strengthening its smart community and hospital solutions. "In BCI, Chinese innovators compete on equal footing globally," notes DNAKE. "Through autonomous R&D and international collaboration, we're poised to shape BCI's future." About DNAKE DNAKE (Xiamen) Intelligent Technology Co., Ltd. is a global leader in smart intercom and home automation solutions. Since 2005, we've delivered innovative, high-quality products—including IP intercoms, cloud platforms, smart sensors, and wireless doorbells—to over 12.6 million households worldwide. Combining cutting-edge technology with customer-focused design, DNAKE provides reliable, scalable solutions for both residential and commercial needs. View original content: SOURCE DNAKE (Xiamen) Intelligent Technology Co., Ltd.
Yahoo
14-07-2025
- Yahoo
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain's functional architecture in rare genetic conditions – – Building and growing a license business is an increasingly important pillar of Firefly's commercial strategy – KENMORE, N.Y., July 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ('Firefly' or the 'Company') (NASDAQ: AIFF), an Artificial Intelligence ('AI') company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to highlight its ongoing collaboration with Prof. Dr. med. Christian Schaaf, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Human Genetics at the Medical Faculty of Heidelberg University, on a groundbreaking study investigating the neurophysiological impact of 15q13.3 copy number variants ('CNVs'). This engagement builds on prior work between Firefly and Prof. Schaaf, including a joint publication on CHRNA7-related phenotypes.1 The current study leverages Firefly's FDA-cleared technology to analyze Electroencephalograms ('EEG') data from 30 subjects — 15 with deletions and 15 with duplications of the 15q13.3 chromosomal region. Study subjects undergo resting state and two cognitive paradigms running automatically through Firefly's BNA platform. The study is scheduled to run through 2026, with Firefly commercially engaged to provide EEG systems, training, and full analytic support, including the comparison to its proprietary, FDA-cleared normative Resting and Event-Related Potential Cognitive tasks database. The study aims to: Identify electrophysiological biomarkers associated with 15q13.3 CNVs; Characterize neurocognitive profiles linked to deletions vs. duplications; and Support future diagnostic and therapeutic strategies for neurodevelopmental disorders. 'This collaboration reflects our shared commitment to advancing precision neuroscience,' said Gil Issachar, Chief Technology Officer of Firefly. 'By combining Heidelberg's clinical expertise with our proprietary technology, we aim to uncover novel insights into the brain's functional architecture in rare genetic conditions. But our mission goes well beyond any single study — deepening our understanding of cognitive disorders, both common and rare, is essential to transforming how we diagnose, monitor, and treat these conditions. Every insight we gain from rare genetic variants like 15q13.3 helps illuminate the broader landscape of neurodevelopmental and neuropsychiatric disorders. We believe that by decoding the brain's electrical language, we can bridge the gap between genotype and phenotype, and ultimately bring more personalized, effective care to patients worldwide.' Greg Lipschitz, Chief Executive Officer of Firefly, said, 'As pharma and medtech organizations increasingly look to leverage the use of objective measures of brain activity such as EEG across various stages of new product development, from ideation up to and including commercialization, there is growing industry awareness and adoption of our highly differentiated, AI-powered technology. We are truly honored that a world-renowned physician scientist, like Prof. Schaaf, is the latest to see the value of his institution licensing our technology, and we look forward to updating our stakeholders as this important research is completed.' Source 1 Stern T, Crutcher EH, McCarthy JM, Ali MA, Issachar G, Geva AB, Peremen Z, Schaaf CP. Brain Network Analysis of EEG Recordings Can Be Used to Assess Cognitive Function in Teenagers With 15q13.3 Microdeletion Syndrome. Front Neurosci. 2021 Jan 28;15:622329. doi: 10.3389/fnins.2021.622329. PMID: 33584189; PMCID: PMC7876406. About Firefly Firefly (NASDAQ: AIFF) is an Artificial Intelligence ('AI') company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly's FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG/ERP system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome. Please visit for more information. About Prof. Christian Schaaf Professor Schaaf is the Medical Director at Heidelberg University Hospital and Department Chair of the Institute of Human Genetics at the Heidelberg University in Germany. He studies the genetic causes of neurodevelopmental and neuropsychiatric disorders, including copy number variants of 15q13.3. His work led to the discovery of multiple new disease genes, and three disorders have been named after him: Schaaf-Yang syndrome, Bosch-Boonstra-Schaaf Optic Atrophy syndrome, and Marbach-Schaaf Neurodevelopmental syndrome. Professor Schaaf's groundbreaking work has been recognized with many awards, including the William K. Bowes Award for Medical Genetics by Partners Healthcare and Harvard Medical School and the inaugural Seldin-Smith Award for Pioneering Research by the American Society for Clinical Investigation. Forward-Looking Statements Certain statements in this press release may constitute 'forward-looking statements' for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly's management teams' expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those factors described under the heading 'Risk Factors' in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Investor & Media ContactStephen Kilmer(646) in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-07-2025
- Yahoo
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain's functional architecture in rare genetic conditions – – Building and growing a license business is an increasingly important pillar of Firefly's commercial strategy – KENMORE, N.Y., July 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ('Firefly' or the 'Company') (NASDAQ: AIFF), an Artificial Intelligence ('AI') company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to highlight its ongoing collaboration with Prof. Dr. med. Christian Schaaf, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Human Genetics at the Medical Faculty of Heidelberg University, on a groundbreaking study investigating the neurophysiological impact of 15q13.3 copy number variants ('CNVs'). This engagement builds on prior work between Firefly and Prof. Schaaf, including a joint publication on CHRNA7-related phenotypes.1 The current study leverages Firefly's FDA-cleared technology to analyze Electroencephalograms ('EEG') data from 30 subjects — 15 with deletions and 15 with duplications of the 15q13.3 chromosomal region. Study subjects undergo resting state and two cognitive paradigms running automatically through Firefly's BNA platform. The study is scheduled to run through 2026, with Firefly commercially engaged to provide EEG systems, training, and full analytic support, including the comparison to its proprietary, FDA-cleared normative Resting and Event-Related Potential Cognitive tasks database. The study aims to: Identify electrophysiological biomarkers associated with 15q13.3 CNVs; Characterize neurocognitive profiles linked to deletions vs. duplications; and Support future diagnostic and therapeutic strategies for neurodevelopmental disorders. 'This collaboration reflects our shared commitment to advancing precision neuroscience,' said Gil Issachar, Chief Technology Officer of Firefly. 'By combining Heidelberg's clinical expertise with our proprietary technology, we aim to uncover novel insights into the brain's functional architecture in rare genetic conditions. But our mission goes well beyond any single study — deepening our understanding of cognitive disorders, both common and rare, is essential to transforming how we diagnose, monitor, and treat these conditions. Every insight we gain from rare genetic variants like 15q13.3 helps illuminate the broader landscape of neurodevelopmental and neuropsychiatric disorders. We believe that by decoding the brain's electrical language, we can bridge the gap between genotype and phenotype, and ultimately bring more personalized, effective care to patients worldwide.' Greg Lipschitz, Chief Executive Officer of Firefly, said, 'As pharma and medtech organizations increasingly look to leverage the use of objective measures of brain activity such as EEG across various stages of new product development, from ideation up to and including commercialization, there is growing industry awareness and adoption of our highly differentiated, AI-powered technology. We are truly honored that a world-renowned physician scientist, like Prof. Schaaf, is the latest to see the value of his institution licensing our technology, and we look forward to updating our stakeholders as this important research is completed.' Source 1 Stern T, Crutcher EH, McCarthy JM, Ali MA, Issachar G, Geva AB, Peremen Z, Schaaf CP. Brain Network Analysis of EEG Recordings Can Be Used to Assess Cognitive Function in Teenagers With 15q13.3 Microdeletion Syndrome. Front Neurosci. 2021 Jan 28;15:622329. doi: 10.3389/fnins.2021.622329. PMID: 33584189; PMCID: PMC7876406. About Firefly Firefly (NASDAQ: AIFF) is an Artificial Intelligence ('AI') company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly's FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG/ERP system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome. Please visit for more information. About Prof. Christian Schaaf Professor Schaaf is the Medical Director at Heidelberg University Hospital and Department Chair of the Institute of Human Genetics at the Heidelberg University in Germany. He studies the genetic causes of neurodevelopmental and neuropsychiatric disorders, including copy number variants of 15q13.3. His work led to the discovery of multiple new disease genes, and three disorders have been named after him: Schaaf-Yang syndrome, Bosch-Boonstra-Schaaf Optic Atrophy syndrome, and Marbach-Schaaf Neurodevelopmental syndrome. Professor Schaaf's groundbreaking work has been recognized with many awards, including the William K. Bowes Award for Medical Genetics by Partners Healthcare and Harvard Medical School and the inaugural Seldin-Smith Award for Pioneering Research by the American Society for Clinical Investigation. Forward-Looking Statements Certain statements in this press release may constitute 'forward-looking statements' for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly's management teams' expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those factors described under the heading 'Risk Factors' in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Investor & Media ContactStephen Kilmer(646)
